What is HC Wainwright’s Forecast for ETON FY2024 Earnings?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Stock analysts at HC Wainwright increased their FY2024 earnings per share estimates for shares of Eton Pharmaceuticals in a research note issued on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.15) per share for the year, up from their previous estimate of ($0.17). HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.15) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q4 2024 earnings at ($0.02) EPS and FY2025 earnings at $0.44 EPS.

Separately, Craig Hallum raised their price target on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday, October 28th.

Eton Pharmaceuticals Stock Performance

NASDAQ ETON opened at $10.03 on Monday. Eton Pharmaceuticals has a one year low of $3.03 and a one year high of $11.11. The stock has a 50-day moving average of $7.50 and a 200 day moving average of $5.04. The company has a market capitalization of $259.14 million, a price-to-earnings ratio of -45.59 and a beta of 1.25.

Insider Activity

In other Eton Pharmaceuticals news, major shareholder Opaleye Management Inc. bought 11,248 shares of Eton Pharmaceuticals stock in a transaction on Monday, October 7th. The stock was acquired at an average cost of $7.22 per share, with a total value of $81,210.56. Following the completion of the acquisition, the insider now owns 2,730,000 shares in the company, valued at approximately $19,710,600. This represents a 0.41 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have bought 85,600 shares of company stock valued at $462,674 in the last ninety days. 14.89% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Nantahala Capital Management LLC bought a new stake in Eton Pharmaceuticals during the 2nd quarter worth approximately $3,095,000. Wasatch Advisors LP bought a new position in Eton Pharmaceuticals in the 3rd quarter worth $1,431,000. Aristides Capital LLC purchased a new stake in Eton Pharmaceuticals in the 2nd quarter worth $658,000. Thompson Siegel & Walmsley LLC bought a new stake in Eton Pharmaceuticals during the second quarter valued at about $420,000. Finally, Stonepine Capital Management LLC bought a new stake in Eton Pharmaceuticals during the second quarter valued at about $362,000. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.